News
ITCI
72.82
-5.05%
-3.87
Analysts Are Bullish on Top Healthcare Stocks: Thermo Fisher (TMO), Intra-Cellular Therapies (ITCI)
TipRanks · 7h ago
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
NASDAQ · 15h ago
BUZZ-Intra-Cellular Therapies slips on $500 mln stock offering
Intra-Cellular Therapies' ITCO.O shares down 3.6% at $73.90 premarket after follow-on offering priced. Biopharma co announced $500 mln stock offering for depression drug. ITCI's shares closed up 23% on Tuesday after drug met main goal in late-stage study.
Reuters · 19h ago
Analysts Conflicted on These Healthcare Names: Intra-Cellular Therapies (ITCI), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF)
TipRanks · 20h ago
Reported Earlier, Intra-Cellular Therapies Prices Public Offering Of 6,849,316 Common Shares At $73/Share
Benzinga · 1d ago
Intra-Cellular Therapies drops 2%, prices $500M equity financing
Healthcare Intra-Cellular Therapies drops 2%, prices $500M equity financing. The stock price is down 2.2% on Wednesday after hours of trade. The company priced its public offering of 6.85M shares at $73.00 per share.
Seeking Alpha · 1d ago
INTRA-CELLULAR THERAPIES INC <ITCI.O>: JEFFERIES RAISES TARGET PRICE TO $105 FROM $100
Reuters · 1d ago
Intra-Cellular Therapies Prices Public Offering Of 6.85 Mln Shares At $73.00/shr
NASDAQ · 1d ago
*All Shares in Offering Will Be Sold by Intra-Cellular Therapies >ITCI
Dow Jones · 1d ago
*Intra-Cellular Therapies Prices Underwritten Public Offering of 6.8M Shares at $73.00 Each >ITCI
Dow Jones · 1d ago
INTRA-CELLULAR THERAPIES INC - PRICING OF ITS PUBLIC OFFERING OF 6.8 MLN SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $73.00 PER SHARE
Reuters · 1d ago
Intra-Cellular Therapies Prices Public Offering of Common Stock
Intra-Cellular Therapies, Inc. Is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders. The company is offering 6,849,316 shares of its common stock at $73.00 per share. The offering is expected to close on April 22, 2024.
Barchart · 1d ago
Wednesday's ETF with Unusual Volume: IHE
NASDAQ · 1d ago
Intra-Cellular Therapies Is Maintained at Neutral by Goldman Sachs
Dow Jones · 1d ago
Intra-Cellular Therapies Price Target Raised to $77.00/Share From $67.00 by Goldman Sachs
Dow Jones · 1d ago
Goldman Sachs Maintains Neutral on Intra-Cellular Therapies, Raises Price Target to $77
Benzinga · 1d ago
Intra-Cellular Therapies Is Maintained at Buy by B of A Securities
Dow Jones · 1d ago
Intra-Cellular Therapies Price Target Raised to $91.00/Share From $82.00 by B of A Securities
Dow Jones · 1d ago
B of A Securities Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $91
Benzinga · 1d ago
Intra-Cellular Therapies Price Target Raised to $103.00/Share From $83.00 by Baird
Dow Jones · 1d ago
More
Webull provides a variety of real-time ITCI stock news. You can receive the latest news about Intra-Cellular Therapies through multiple platforms. This information may help you make smarter investment decisions.
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.